From GlobeNewswire: 2025-05-14 08:00:00

Kala Bio, Inc. is actively enrolling patients in the Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect, with topline data expected by 3Q 2025. They have cash resources of $42.2 million as of March 31, 2025, which should fund operations into 1Q 2026.

Kala Bio is focused on developing KPI-012, a therapy with a multifactorial mechanism of action to address corneal healing impairments in severe ocular diseases. They aim to target a broad indication for Persistent Corneal Epithelial Defect, a condition with an estimated 100,000 patients in the U.S.

The company is also exploring the potential of KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases. Additionally, Kala is conducting preclinical studies for KPI-014, which may offer a gene-agnostic approach for inherited retinal degenerative diseases like Retinitis Pigmentosa.

Financially, as of March 31, 2025, Kala Bio had $42.2 million in cash and cash equivalents, a decrease from $51.2 million in December 2024 due to operational expenses. They reported a net loss of $8.9 million for the first quarter of 2025, with ongoing efforts to advance their innovative therapies for rare and severe eye diseases.



Read more at GlobeNewswire:: KALA BIO Reports First Quarter 2025 Financial Results and